Revance Therapeutics traded at $17.47 this Tuesday August 9th, decreasing $1.87 or 9.67 percent since the previous trading session. Looking back, over the last four weeks, Revance Therapeutics lost 15.24 percent. Over the last 12 months, its price fell by 34.62 percent. Looking ahead, we forecast Revance Therapeutics to be priced at 19.11 by the end of this quarter and at 17.56 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 140.25 -0.09 -0.06% 22.15%
Aerie Pharmaceuticals 11.23 0.57 5.35% -20.07%
ALKERMES 25.60 -0.15 -0.58% -10.65%
Bristol-Myers Squibb 74.96 1.16 1.57% 12.10%
Cara Therapeutics 11.81 0.31 2.70% -9.08%
Coherus Biosciences 11.06 -0.35 -3.07% -16.21%
Endo International 0.40 -0.27 -39.67% -90.74%
Horizon Pharma 67.12 -2.53 -3.63% -36.08%
Jazz Pharmaceuticals 156.55 2.44 1.58% 8.24%
J&J 170.18 -0.02 -0.01% -2.07%
Eli Lilly 303.02 0.52 0.17% 14.74%
Merck & Co 89.52 1.03 1.16% 19.06%
Neurocrine Biosciences 107.66 3.07 2.94% 23.48%
Pacira 58.32 -0.19 -0.32% 3.85%
P&G 144.93 -0.34 -0.23% 1.87%
Revance Therapeutics 17.47 -1.87 -9.67% -34.62%
Supernus Pharmaceuticals 31.02 -0.25 -0.80% 25.84%
Teva Pharmaceutical Industries 11.00 -0.03 -0.27% 8.91%

Indexes Price Day Year
USND 12494 -150.53 -1.19% -15.51%
US2000 1913 -28.31 -1.46% -14.58%

Revance Therapeutics
Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.